Anti-S100A8 Antibody (FITC)

1/1
Price:
Size:
Number:

Anti-S100A8 Antibody (FITC) (Mouse Monoclonal antibody) General Information

Product name
Anti-S100A8 Antibody (FITC)
Validated applications
FCM
Species reactivity
Reacts with: Human
Specificity
Human S100A8
Immunogen
Recombinant Human S100A8 Protein (Catalog#11138-H08B)
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human S100A8 (rh S100A8; Catalog#11138-H08B; NP_002955.2; Met1-Glu93) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
Source
Monoclonal Mouse IgG1 Clone #07
Purification
Protein A
Formulation
Aqueous solution containing 0.5% BSA and 0.03%ProClin300
Conjugate
FITC
Concentration
5 μl/Test, 0.1 mg/ml
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze !

Anti-S100A8 Antibody (FITC) (Mouse Monoclonal antibody) Images

Flow cytometric analysis of Human S100A8 expression on human whole blood Granulocytes. The cells were treated according to manufacturer’s manual (BD Pharmingen™ Cat. No. 554714), stained with FITC-conjugated anti-Human S100A8. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable Granulocytes.

Anti-S100A8 Antibody (FITC): Alternative Names

Anti-60B8AG Antibody; Anti-CAGA Antibody; Anti-CFAG Antibody; Anti-CGLA Antibody; Anti-CP-10 Antibody; Anti-L1Ag Antibody; Anti-MA387 Antibody; Anti-MIF Antibody; Anti-MRP-8 Antibody; Anti-MRP8 Antibody; Anti-NIF Antibody; Anti-P8 Antibody

S100A8 Background Information

S1A8 is a member of the S1 protein family containing 2EF-hand calcium-binding motifs. S1 proteins are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. Altered expression of S1A8 protein is associated with various diseases and cancers. S1A8 may have an immunoregulatory role by contributing to the regulation of fetal-maternal interactions. It may play a protective role and its absence may allow infiltration by maternal cells, a process eventually manifesting as resorption. The heterodimeric S1 protein complex S1A8/A9 which has been shown to be involved in inflammatory and neoplastic disorders. The complex can induce cell proliferation, or apoptosis, inflammation, collagen synthesis, and cell migration. S1A8/A9 has emerged as important pro-inflammatory mediator in acute and chronic inflammation. More recently, increased S1A8 and S1A9 levels were also detected in various human cancers, presenting abundant expression in neoplastic tumor cells as well as infiltrating immune cells. On the one hand, S1A8/A9 is a powerful apoptotic agent produced by immune cells, making it a very fascinating tool in the battle against cancer. It spears the risk to induce auto-immune response and may serve as a lead compound for cancer-selective therapeutics. In contrast, S1A8/A9 expression in cancer cells has also been associated with tumor development, cancer invasion or metastasis. Altogether, its expression and potential cytokine-like function in inflammation and in cancer suggests that S1A8/A9 may play a key role in inflammation-associated cancer.
Full Name
S100 calcium binding protein A8
References
  • Passey RJ, et al. (1999) S100A8: emerging functions and regulation. J Leukoc Biol. 66(4): 549-56.
  • Gebhardt C, et al. (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 72(11): 1622-31.
  • Halayko AJ, et al. (2009) S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol. 87(10): 743-55.
  • Ghavami S, et al. (2009) S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 625(1-3): 73-83.
  • Ha YS, et al. (2010) mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean J Urol. 51(1): 15-20.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait